8.12亿美元!诺和诺德又出手了,押注Deep Apple,布局肥胖症新靶点

药时代
Jun 11, 2025

正文共1650字 2图预计阅读时间4分钟药时代报道2025年6月11日,全球领先的糖尿病和肥胖症治疗企业诺和诺德(Novo Nordisk)与生物技术公司Deep Apple Therapeutics宣布达成一项价值8.12亿美元的合作协议,旨在开发针对非肠促胰岛素G蛋白偶联受体(GPCR)靶点的小分子药物。(图片来源:Deep Apple Therapeutics)这一举措标志着诺和诺德在肥胖症...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10